Asset profile
Dorzagliatin · Huatangning
Small molecule
Evidence outlook · registrational
Type 2 Diabetes: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. No upcoming registrational readout date is posted to the registry — check News for topline announcements.
NCT04531631: The study used randomized, triple-blind, placebo-controlled crossover treatment, but enrolled only 18 participants and measured a mechanistic insulin-response biomarker rather than a clinical diabetes outcome. Because the registry provides no primary-endpoint results, it is not possible to determine whether the comparison met its prespecified endpoint.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.